High-Dose CBD Was Neither Effective Nor Toxic for Huntington's Disease in a Controlled Trial | Research

The takeaway

In a double-blind crossover trial, CBD at approximately 700 mg/day for six weeks produced no significant improvement in Huntington's disease symptoms compared to placebo, but was also well tolerated with no safety concerns.

Read this if you want to see a controlled trial where CBD did not work for a neurological condition, an important counterpoint to overly optimistic CBD claims.

No significant differences between CBD (700 mg/day) and placebo on any HD outcome

What the researchers found

Based on encouraging preliminary findings, researchers conducted a rigorous controlled trial of CBD in 15 Huntington's Disease patients who were not taking neuroleptic medications.

Patients received either oral CBD (10 mg/kg/day, averaging about 700 mg/day) or placebo (sesame oil) for six weeks each in a double-blind, randomized crossover design. The primary outcome was chorea severity, the involuntary jerking movements characteristic of HD.

CBD produced no significant differences from placebo on chorea severity or any other therapeutic outcome measure. It was also not toxic: clinical lab tests, a cannabis side effect inventory, and other safety measures showed no significant differences from placebo.

Plasma CBD levels were consistent across the six weeks (mean range 5.9 to 11.2 ng/mL), confirming patients were absorbing the drug. The conclusion was straightforward: at this dose and duration, CBD was neither helpful nor harmful for HD.

Why it matters

This was one of the first rigorous controlled trials of CBD for a neurodegenerative disease. While the negative result was disappointing, it was scientifically important: it demonstrated that CBD does not universally benefit all neurological conditions and established a safety profile at high doses.

The numbers in context

15 patients. CBD dose: 10 mg/kg/day (approximately 700 mg/day). Duration: 6 weeks per phase. Plasma CBD: 5.9 to 11.2 ng/mL. No significant differences on any outcome (P > 0.05).

How the study worked

Double-blind, randomized crossover trial in 15 neuroleptic-free Huntington's Disease patients. CBD (10 mg/kg/day) and placebo (sesame oil) were each administered for 6 weeks. Weekly assessments included chorea severity, therapeutic outcomes, side effects, clinical lab tests, and plasma CBD levels by GC/MS.

What this study cannot tell us

Fifteen patients is a small sample. Six weeks may be too short to detect slowly developing benefits. The crossover design assumes no carryover effects. Plasma CBD levels were relatively low despite high oral doses, suggesting poor bioavailability.

How to read the evidence

A well-designed double-blind, randomized crossover RCT, but with only 15 patients. The rigorous design adds confidence to the negative finding.

When this study was published

Published in 1991. CBD research has expanded enormously, but large-scale trials for neurodegenerative diseases remain limited.

The bigger picture

This negative result is a useful counterpoint to the tendency to assume CBD helps all neurological conditions. HD involves specific pathology (striatal neuron degeneration) that may not respond to CBD's mechanism of action. The study's well-tolerated safety profile at 700 mg/day, however, supported future CBD research in other conditions.

Questions still open

Would longer treatment duration produce different results? Would higher plasma levels (achievable via different formulations) be effective? Why were preliminary findings encouraging but the controlled trial negative?

Common questions

Did CBD help Huntington's Disease?

No. In this controlled trial, CBD at approximately 700 mg/day for six weeks produced no significant improvement in chorea or any other HD symptom compared to placebo.

Was CBD safe at this dose?

Yes. At approximately 700 mg/day for six weeks, CBD produced no significant side effects or laboratory abnormalities compared to placebo.

Read the original research

Controlled clinical trial of cannabidiol in Huntington's disease.

Pharmacology, biochemistry, and behavior, 40(3), 701-8

View on PubMed ↗

Citation

Consroe, P; Laguna, J; Allender, J; Snider, S; Stern, L; Sandyk, R; Kennedy, K; Schram, K. (1991). Controlled clinical trial of cannabidiol in Huntington's disease.. Pharmacology, biochemistry, and behavior, 40(3), 701-8.